v3.26.1
Consolidated Statement of Cash Flows - EUR (€)
€ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Consolidated Statement of Cash Flows      
Net profit / (loss) (-) € 320,884 € 74,082 € 211,697
Increase in provisions 45,499    
Impairment of the cell therapy business 228,112    
Adjustment for non-cash transactions 127,160 (4,909) 99,291
Adjustment for items to disclose separately under operating cash flow (63,443) (89,644) (65,763)
Adjustment for items to disclose under investing and financing cash flows (42,254) (76,239) (16,688)
Change in working capital other than deferred income 149,252 (61,445) (31,373)
Cash used for other liabilities related to the acquisition of subsidiaries (1,792)    
cash used for other liabilities related to the disposal of subsidiaries   (3,598)  
Decrease in deferred income (1,071,319) (255,508) (661,062)
Cash used in operations (307,901) (417,261) (463,898)
Interest paid (464) (689) (3,809)
Interest received 51,281 97,518 69,907
Income taxes paid (372) 406 (8,170)
Net cash flows used in operating activities (257,456) (320,026) (405,970)
Purchase of property, plant and equipment (13,704) (16,720) (18,706)
Purchase of and expenditure in intangible fixed assets (155) (65,390) (567)
Proceeds from disposal of property, plant and equipment 462 3 2,426
Purchase of financial investments (3,465,056) (3,349,406) (3,390,178)
Investment income received related to current financial investments 60,448 29,498 14,765
Sale of current financial investments 3,684,643 3,668,441 3,484,411
Proceeds from settlement of hedging instrument 22,745    
Cash out from disposal of subsidiaries, net of cash disposed of 19,431 (8,949)  
Cash out from acquisition of subsidiaries, net of cash acquired     (7,000)
Cash advances and loans to third parties (20,000)    
Acquisition of financial assets held at fair value   (36,880) (13,965)
Net cash flows generated from/used in (-) investing activities 288,814 220,597 71,186
Payment of lease liabilities and other debts (3,273) (4,924) (6,771)
Proceeds from capital and share premium increases from exercise of subscription rights     1,770
Net cash flows used in financing activities (3,273) (4,924) (5,001)
Increase/decrease (-) in cash and cash equivalents 28,085 (104,353) (339,785)
Cash and cash equivalents at beginning of year 64,239 166,810 508,117
Effect of exchange rate differences on cash and cash equivalents (4,456) 1,782 (1,522)
Cash and cash equivalents at end of year € 87,868 € 64,239 € 166,810